Achievements

Industry achievements

Owkin

  • Developed and maintained 3 Snakemake pipelines that have been used to process multimodal data from >1500 patients from MOSAIC.
  • Led data science strategy for 1 internal target discovery programme that led to investment in wet lab experiments.
  • Built 2 machine learning pipelines from scratch for drug positioning and target identification that are now part of our client offerings.
  • Presented a poster at Spatial Biology UK conference.
  • Presented a poster at ISMB/ECCB 2025 conference.

Benevolent AI

  • Delivered research report to AstraZeneca as tech lead on target discovery programme - work that ultimately led to target nomination.
  • Successfully managed to completion an intern working on multi-omics integration metho benchmarking.
  • Led an internal target discovery programme from conception, data science strategy, implementation and finally to the delivery of targets for validation by drug discovery teams.

Publications

MOSAIC: Intra-tumoral heterogeneity characterization through large-scale spatial and cell-resolved multi-omics profiling * Here is our preprint introducing MOSAIC. * As part of the MOSAIC consortium I built several of the data processing pipelines from scratch and scaled them to 1000s patient samples. * I was not involved in the writing of the paper.

Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations

Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer * In this study I carried out the human ’omics analysis. * I characterised the prognostic potential of FOLR2+ tissue resident macrophages in breast cancer.

NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer

RNA sensing via the RIG‐I‐like receptor LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency

Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy

Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade * This study formed a large part of my PhD in which I translated critical findings from syngeneic mouse models into human. * I performed all of the ’omics analysis in this paper identifying a Cyclooxygenase-2 activity related gene signature that was associated with patient prognosis and response to checkpoint inhibitors.

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells

Awards

  • Biomarker patent (WO-2019243567-A1).
  • Medical Research Council Confidence-in-Concept £60,000 grant for analytical validation and optimisation of putative biomarker.
  • Manchester Biomedical Research Centre £10,000 grant for GeoMx spatial transcriptomics study in triple-negative breast cancer.
  • Biomedical Science Award 2015 at University of Sheffield.

Conferences

2025 ISMB ECCB 2025, Liverpool I attended ISMB ECCB 2025 in Liverpool on behalf of Owkin where I presented a poster all about our work quantifying hallmarks of ADC response from MOSAIC data.

2024
Spatial Biology UK, London
Last year I attended the Spatial Biology UK 2024 conference in London on behalf of the MOSAIC research team at Owkin. Here I am with our poster.

2022 Computational biology and in silico discovery, EMBL EBI, Heidelberg Attended on behalf of Benevolent AI.

2019 International PhD Students in Cancer Netherlands Cancer Institute Here’s me getting a poster award from Nobel prize winner Ben Feringa at the International PhD Students in Cancer Conference 2019.